Clinical Study of XP-004 Personalized mRNA Tumor Vaccine Combined With PD-1 Inhibitor for Postoperative Adjuvant Therapy for Pancreatic Cancer in Patients With Advanced Solid Tumors

The main purpose of this study is to observe and evaluate the safety and tolerance of XP-004 personalized mRNA vaccine encoding tumor neoantigen combined with PD-1 inhibitor for adjuvant treatment of patients who cannot tolerate chemotherapy after radical resection of pancreatic cancer.
The secondary objective was to observe the initial efficacy of adjuvant therapy with XP-004 personalized mRNA vaccine combined with PD-1 inhibitor in patients with pancreatic cancer after radical surgery by the indicators of XP-004 personalized mRNA vaccine induced activstion of Antigen specific CD4 and CD8 T cells, Recurrence free survival (RFS), and Overall Survival (OS).

开始日期2024-04-01

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

NCT05916248 / Recruiting临床1期IIT

Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pembrolizumab in Patients With Advanced Solid Tumors

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of advanced solid tumors. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

开始日期2023-05-18

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

NCT05916261 / Recruiting早期临床1期IIT

Clinical Study of Personalized Tumor Vaccines mRNA-0217/S001 and Pabolizumab in Patients With Advanced Pancreatic Cancer

The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of Advanced Pancreatic Cancer. The secondary objective was to observe the preliminary efficacy of mRNA-0217/S001 personalized tumor vaccine in the treatment of advanced solid tumors with neoantigen-specific CD4+ and CD8+ T lymphocyte responses, objective tumor response rate (ORR) and disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) caused by mRNA-0217/S001 personalized tumor vaccine.

开始日期2023-04-26

申办/合作机构

上海交通大学医学院附属瑞金医院

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的临床结果

登录后查看更多信息

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的转化医学

登录后查看更多信息

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的专利（医药）

登录后查看更多信息

100 项与 Personalized neoantigen tumor vaccine(Ruijin Hospital) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胰腺癌	临床1期	中国	上海交通大学医学院附属瑞金医院	2024-04-01
晚期恶性实体瘤	临床1期	中国	上海交通大学医学院附属瑞金医院	2023-05-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2021	N/A	星形细胞瘤	1	Personalized DNA neoantigen vaccine	(壓網憲艱遞願繭構艱遞) = grade 1 襯繭夢鬱廠齋鹽淵壓蓋 (鏇積範願憲簾構鑰鏇窪 )	-	2021-05-28